

#### **Case history & physical exam**

#### History:

- 46 year old banker
- 2 month history of nonproductive cough
- 15 pound weight loss
- Smoked 1 PPD for 30 years


#### Physical Exam:


- Decreased breath sounds over right lower lobe
- Dullness to percussion lower right lung





# Lung Cancer Epidemiology


- 238,340 new cases per year
- 127,070 U.S. deaths annually
- Lifetime risk:
  - 1:15 men
  - 1:17 women























#### **Risk Factors For Lung Cancer**


# Smoking


- Environmental tobacco smoke
- Genetics
- Radon
- Asbestos
- Radiation therapy
- Emphysema
- Pulmonary fibrosis











#### **Common presenting symptoms of lung cancer:**

- Cough
- Hemoptysis
- Chest pain
- Hoarseness
- Dyspnea
- Malaise/anorexia




#### Making A Tissue Diagnosis:

- Sputum cytology Bronchoscopy CT-guided needle biopsy Thoracentesis Endobronchial ultrasound Mediastinoscopy Thoracotomy/VATS
- When Used Rarely Commonly Occasionally Occasionally Occasionally Occasionally Commonly

#### How Used

- Large central lesions
- Lesions > 2 cm
- Peripheral lesions
  - Pleural effusion
- Large lymph nodes
- Large lymph nodes
- Other tests indeterminate



#### **Case Bronchoscopic Findings**





- Endobronchial tumor involving RML and RLL
- Biopsy = large cell undifferentiated lung cancer


# **Staging System For Lung Cancer**

- T = <u>Tumor</u>
  - 0-4; subcategorized as "a", "b", & "c"
  - based on size & location
- N = <u>Nodes</u>
  - 0-3
  - based on location of involved lymph nodes
- M = <u>Metastases</u>
  - 0-1; subcategorized as "a", "b", & "c"
  - Based on presence or absence of metastases

TNM Score Determines Stage				
T/M	N0	N1	N2	N3
T1a	IA1	IIB	IIIA	IIIB
T1b	IA2	IIB	IIIA	IIIB
T1c	IA3	IIB	IIIA	IIIB
T2a	IB	IIB	IIIA	IIIB
T2b	IIA	IIB	IIIA	IIIB
Т3	IIB	IIIA	IIIB	IIIC
T4	IIIA	IIIA	IIIB	IIIC
M1a/b	IVA	IVA	IVA	IVA
M1c	IVB	IVB	IVB	IVB








#### Staging approach for non-small cell lung cancer

- History & physical examination
- Labs: CBC, chemistry profile, calcium, liver enzymes
- Chest CT
- PET scan (in clinical stage IB, IIA, and IIB)
- Other imaging studies if metastases suspected
- Bronchoscopy with EBUS or mediastinoscopy if lymph nodes are large
- Biopsy abnormal sites if it will affect management


# **Chest CT**

- Advantages:
  - Excellent determination of calcification patterns
  - Provides guide to bronchoscopy & mediastinoscopy

- Disadvantages:
  - Large number of false positive adrenal masses (approximately 2/3 of adrenal masses will be benign)
  - Large number of false positive lymph nodes



# **PET-CT Scans In Lung Cancer Staging**





#### Disadvantages:


- Poor for "T" staging
- Poor for brain metastases
- False positives common

#### Advantages:

- Improved detection of mediastinal involvement
- Improved detection of distant metastases














# Non-Small Cell Lung Cancer Treatment Stage Ia Surgery Stage Ib Surgery (with possible adjuvant chemotherapy, immunotherapy, and/or osimertinib\*) Stage II Surgery + adjuvant chemotherapy, immunotherapy, and/or osimertinib\* Stage II Chemotherapy ± radiation therapy followed by immunotherapy. Possible late surgery Stage IV Chemotherapy ± Immunotherapy or driver-directed treatment \*Adjuvant chemotherapy = cisplatin + second drug Immunotherapy if PD-L1 ≥ 1% Osimertinib if tumor is EGFR positive

#### Pre-op evaluation\*

- <u>PFTs</u>: FEV1 & DLCO > 80% desirable
- If FEV1 and/or DLCO are < 80%
  - The predicted post-operative FEV1 and DLCO should be calculated, typically using quantitative ventilation/perfusions scans
  - A low tech exercise test (ability to walk up 5 flights of stairs) or high tech exercise test (cardiopulmonary exercise test) should be performed.
- <u>ABG</u>: PCO2 < 45 desirable (?)</p>

\*Never Miss An Opportunity To Refer A Surgically Curable Patient For Surgery!

#### Cardiopulmonary Exercise Testing For The Patient With A Marginal FEV1:

- mVO2 > 20 ml/kg/min
  - Surgery
- mVO2 < 10 ml/kg/min:
  - Surgery is too high risk
- mVO2 10-20 ml/kg/min:
  - Possible surgery
  - Consider pulmonary rehabilitation first

#### **Case Outcome:**

- Stage IIB
- Pre-op FEV1 = 2.74 liters (70% of predicted)
- Predicted post-op FEV1 = 50% of predicted
- Able to easily walk up 5 flights of stairs
- ABG: PCO2 = 40 (normal)

- Underwent right middle and lower lobe resection
- Cancer free 30 years later

# **Small Cell Lung Cancer**

#### Limited Stage:

- 30% of patients
- Average survival = 17 months
- Treatment:
  - Stage I: surgery plus chemotherapy
  - Stage II & III: radiation plus chemotherapy
  - Prophylactic cranial radiation recommended
- Cure rate = 20%

#### **Extensive Stage:**

- 70% of patients
- Average survival = 12 months
- Treatment: chemotherapy ± immunotherapy
- Cure rate = 1 2%

Small cell lung cancer is essentially never curable by surgery alone!!!

# Staging approach to small cell lung cancer\*


- Chest CT
- Abdominal CT
- Pelvic CT
- Lab tests
- Brain MRI (or head CT)
- PET scan

\*Staging should not delay starting chemotherapy and is mainly to determine whether radiation should be given (limited stage)

# **Inoperable** ≠ **Untreatable**

#### Medical Treatment of Advanced Non-Small Cell Lung Cancer in 2025

- Driver mutations can guide treatment:
  - EGFR (+) --- EGFR tyrosine kinase inhibitors such as osimertinib
  - ALK (+) --- ALK tyrosine kinase inhibitors such as <u>alectinib</u>
  - BRAF (+) BRAF/MEK inhibitors such as dabrafenib and trametinib
  - ROS1 (+) ROS1 inhibitor <u>crizotinib</u>
  - Others: MET, RET, NTRK, KRAS




# In 10 years, the preferred treatments for advanced nonsmall cell lung cancer will have changed... a lot

#### Tomorrow's Patients Will Owe Their Lives To Today's Patients In Clinical Trials

# **Palliation of Lung Cancer**

- External beam radiation
- Brachytherapy
- Cryotherapy
- Argon plasma coagulation
- Stents
- Photodynamic therapy
- Laser
- Pleurodesis


#### 68 Year Old Man With Tracheal Squamous Cell Carcinoma





Trachea Pre-Stent



Trachea Post-Stent







#### Results of screening chest CTs:

- Lung cancers found in earlier stages
- Overall, 20% reduction in mortality
- High false positive rate:
  - Overall 30% of CT scans were abnormal
  - A suspicious abnormality was 27 times more likely to be benign than malignant
- Screening CTs plus follow-up CTs are very expensive

# Medicare Lung Cancer Screening Requirements:


- Age 50-80
- Asymptomatic
- More than 20 pack-year smoking history
- Current smoker or quit in the past 15 years
- Counseling session that includes risks/benefits of screening and includes smoking cessation counseling

\*Continue screening annually until > 15 years since quit smoking

# What do you do about the incidentally identified solitary pulmonary nodule?


# Indicators of benign pulmonary nodules


- Calcification patterns
- Age
- Smoking history
- Size
- History of cancer
- Radiographically stable over time



#### PET Scan And The Solitary Pulmonary Nodule


- False negatives in:
  - Well-differentiated adenocarcinomas
  - Carcinoid tumors
  - Hyperglycemia
  - Tumors < 8 mm</li>
- False positives in:
  - Tuberculosis
  - Fungal infections
  - Sarcoidosis















#### The average smoker loses 14 minutes of life for every cigarette smoked























#### Smoking is a *childhood* epidemic Any tobacco product 90% of smokers E-cigarettes 5.9% begin before age 18 Nicotine pouches 1.8% 1.4% Cigarettes 10.1% of high **Current Tobacco** Cigars 1.2% school students and **Product Use** Smokeless tobacco 1.2% 5.4% of middle Among U.S. Middle Other oral 1.2% school students use products and High School tobacco products 0.8% Students in 2024 0.7% Pipe tobacco 0.5% CDC Source: National Youth Tobacco Survey, 2024

